Saturday 17 October 2026
Export RADX’s income statement to Excel — free account
Radiopharm Theranostics Limited - Sponsored ADR
RADX Healthcare Biotechnology
Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.
1.03
0.05
−4.63%
Follow RADX
| Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|
Piotroski F-Score |
— | — | 3 |
Altman Z-Score |
— | (2.74) | (6.65) |
Altman Z″-Score (non-manufacturers) |
(8.32) | (5.54) | (16.22) |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | 55.66 | (2.62) |
P/Operating CF |
0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | 0.03 |
EV/FCF |
0.00 | 0.00 | 0.03 |
Quick Ratio |
1.11 | 2.65 | 1.14 |
Current Ratio |
1.30 | 2.67 | 1.16 |
Net Debt/EBITDA |
0.42 | 0.82 | 0.08 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.05 | 0.04 |
Operating CF/Net income |
0.48 | 0.96 | 0.93 |
Capex/Depreciation |
0.00 | 1.15 | 0.00 |
Interest Coverage |
(73.43) | (584.43) | (505.10) |
| 0.00% | (108.66%) | (180.13%) | |
| 0.00% | (48.10%) | (79.84%) | |
ROIC |
(336.13%) | (173.45%) | (195.15%) |
Return on Tangible Assets |
(899.05%) | (153.53%) | (1,852.14%) |
Average Days of Receivables |
1,204.57 | 1,044.76 | 2,300.75 |
Research and Development Expense of Revenue |
7,716.62% | 757.28% | 1,805.06% |
Selling, General and Administrative Expense of Revenue |
5,240.88% | 455.04% | 672.76% |
Intangible Assets out of Total Assets |
0.68 | 0.54 | 0.63 |
Share Based Compensation of Revenue |
882.47% | 52.16% | 86.92% |
Graham Net Nets |
0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% |
Revenue per Share |
0.15 | 0.34 | 0.18 |
Operating CF per Share |
(11.70) | (3.42) | (3.50) |
Capex per Share |
0.00 | 0.28 | 0.00 |
Free Cash Flow per Share |
(11.70) | (3.14) | (3.50) |
Cash per Share |
9.46 | 2.72 | 0.27 |
Shareholders Equity per Share |
13.93 | 4.00 | 1.48 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
13.93 | 4.00 | 1.48 |
Free Cash Flow |
(15.07) | (21.79) | (35.82) |
Working Capital |
3.46 | 16.14 | 2.06 |
Capital Expenditures |
— | 1.94 | — |
Net Current Asset Value |
(14.32) | (2.43) | (10.78) |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | (0.82) | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
51.38 | 48.58 | 58.68 |
Cash ROIC |
(50.03%) | (46.74%) | (199.47%) |
Accounts Receivable Turnover |
0.00 | 0.64 | 0.20 |
Accounts Payable Turnover |
— | 0.35 | 0.26 |
Inventory Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 948.60 | 1,534.88 |
Days of Inventory on Hand |
— | 0.00 | 0.00 |
Average Receivables |
— | 3.69 | 9.29 |
Average Payables |
— | 6.58 | 6.60 |
Average Assets |
— | 51.62 | 48.41 |
Average Common Equity |
— | 22.85 | 21.46 |
Columns are period end dates · fundamentals updated 16 Oct 2026